4:07 PM
 | 
Mar 14, 2018
 |  BC Extra  |  Financial News

Foghorn launches with $50M for chromatin remodeling platform

Flagship Pioneering's Flagship VentureLabs launched chromatin remodeling company Foghorn Therapeutics Inc. (Cambridge, Mass.) with a $50 million capital commitment. Foghorn's Gene Traffic Control platform identifies small molecules capable of regulating chromatin remodeling complexes, which determine whether particular genes are physically accessible for transcription and eventually expressed as protein.

Foghorn President and CEO Adrian Gottschalk told BioCentury that the initial focus will be on modulating...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >